Literature DB >> 25516664

Genomic landscape of pancreatic neuroendocrine tumors.

Niklas Gebauer1, Christian Schmidt-Werthern1, Veronica Bernard1, Alfred C Feller1, Tobias Keck1, Nehara Begum1, Dirk Rades1, Hendrik Lehnert1, Georg Brabant1, Christoph Thorns1.   

Abstract

AIM: To investigate the prognostic role of genomic stability and copy number alterations (CNAs) pancreatic neuroendocrine tumors (PanNETs).
METHODS: A high-resolution array-based comparative genomic hybridization approach was utilized in order to investigate and quantify chromosomal aberrations in a panel of 37 primary PanNET and 11 metastatic samples. DNA samples were extracted from formalin-fixed and paraffin-embedded tumor specimen. Genomic findings were correlated with histopathological and immunohistochemical data. Moreover, the dataset was subjected to employing an unsupervised hierarchical clustering analysis approach utilizing Euclidean distance and average linkage and associations between genomically defined tumor groups and recurrent CNAs or clinicopathological features of the study group were assessed.
RESULTS: Numerous chromosomal aberrations were recurrently detected in both, primary tumor samples and metastases. Copy number gains were most frequently observed at 06p22.2-p22.1 (27.1%), 17p13.1 (20.8%), 07p21.3-p21.2 (18.8%), 09q34.11 (18.8%). Genomic losses were significantly less frequent and the only recurrent aberration affected 08q24.3 (6.3%). Moreover, we detected a high degree of genomic heterogeneity between primary tumors and metastatic lesions. Unsupervised hierarchical clustering of loci affected by CNAs in more than 3 primary tumor samples revealed two genetically distinct tumor groups as well as two chromosomal clusters of genomic imbalances indicating a small subset of tumors with common molecular features (13.5%). Aberrations affecting 6p22.2-22.1, 8q24.3, 9q34.11 and 17p13.1 (P = 0.011; 0.003; 0.003; 0.001), were significantly associated with a poorer survival prognosis.
CONCLUSION: This study suggests that several frequent CNAs in numerous candidate regions are involved in the pathogenesis and metastatic progression of PanNET.

Entities:  

Keywords:  Array comparative genomic hybridization; Chromosomal aberrations; Copy number alterations; Pancreatic neuroendocrine tumors; Prognosis

Mesh:

Substances:

Year:  2014        PMID: 25516664      PMCID: PMC4265611          DOI: 10.3748/wjg.v20.i46.17498

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  33 in total

1.  Genesis: cluster analysis of microarray data.

Authors:  Alexander Sturn; John Quackenbush; Zlatko Trajanoski
Journal:  Bioinformatics       Date:  2002-01       Impact factor: 6.937

2.  Chromosome 18 deletions are common events in classical midgut carcinoid tumors.

Authors:  R M Löllgen; O Hessman; E Szabo; G Westin; G Akerström
Journal:  Int J Cancer       Date:  2001-06-15       Impact factor: 7.396

3.  Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases.

Authors:  W Kimura; A Kuroda; Y Morioka
Journal:  Dig Dis Sci       Date:  1991-07       Impact factor: 3.199

4.  Status of the p53, p16, RB1, and HER-2 genes and chromosomes 3, 7, 9, and 17 in advanced bladder cancer: correlation with adjacent mucosa and pathological parameters.

Authors:  M Gallucci; F Guadagni; R Marzano; C Leonardo; R Merola; S Sentinelli; E M Ruggeri; R Cantiani; I Sperduti; F de la Iglesia Lopez; A M Cianciulli
Journal:  J Clin Pathol       Date:  2005-04       Impact factor: 3.411

5.  Chromosomal aberrations in colorectal cancers and liver metastases analyzed by comparative genomic hybridization.

Authors:  H Aragane; C Sakakura; M Nakanishi; R Yasuoka; Y Fujita; H Taniguchi; A Hagiwara; T Yamaguchi; T Abe; J Inazawa; H Yamagishi
Journal:  Int J Cancer       Date:  2001-12-01       Impact factor: 7.396

6.  Gains of 12q are the most frequent genomic imbalances in adult fibrosarcoma and are correlated with a poor outcome.

Authors:  H Schmidt; H Taubert; P Würl; M Kappler; H Lange; F Bartel; M Bache; H-J Holzhausen; R Hinze
Journal:  Genes Chromosomes Cancer       Date:  2002-05       Impact factor: 5.006

7.  Genomic alterations in well-differentiated gastrointestinal and bronchial neuroendocrine tumors (carcinoids): marked differences indicating diversity in molecular pathogenesis.

Authors:  J Zhao; R R de Krijger; D Meier; E J Speel; P Saremaslani; S Muletta-Feurer; C Matter; J Roth; P U Heitz; P Komminoth
Journal:  Am J Pathol       Date:  2000-11       Impact factor: 4.307

8.  Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas.

Authors:  Maria A Kouvaraki; Jaffer A Ajani; Paulo Hoff; Robert Wolff; Douglas B Evans; Richard Lozano; James C Yao
Journal:  J Clin Oncol       Date:  2004-12-01       Impact factor: 44.544

Review 9.  Neuroendocrine tumors of the pancreas: current concepts and controversies.

Authors:  Michelle D Reid; Serdar Balci; Burcu Saka; N Volkan Adsay
Journal:  Endocr Pathol       Date:  2014-03       Impact factor: 3.943

10.  Malignant pancreatic endocrine tumor in a child with tuberous sclerosis.

Authors:  Paola Francalanci; Francesca Diomedi-Camassei; Cristina Purificato; Filippo Maria Santorelli; Aldo Giannotti; Carlo Dominici; Alessandro Inserra; Renata Boldrini
Journal:  Am J Surg Pathol       Date:  2003-10       Impact factor: 6.394

View more
  9 in total

1.  Site-Specific Genomic Alterations in a Well-Differentiated Pancreatic Neuroendocrine Tumor With High-Grade Progression.

Authors:  David R Martin; Elisa LaBauve; Joseph M Pomo; Vi K Chiu; Joshua A Hanson; Rama R Gullapalli
Journal:  Pancreas       Date:  2018-04       Impact factor: 3.327

Review 2.  Clinical and Preclinical Advances in Gastroenteropancreatic Neuroendocrine Tumor Therapy.

Authors:  Judy S Crabtree
Journal:  Front Endocrinol (Lausanne)       Date:  2017-12-04       Impact factor: 5.555

3.  The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines.

Authors:  Tobias Hofving; Yvonne Arvidsson; Bilal Almobarak; Linda Inge; Roswitha Pfragner; Marta Persson; Göran Stenman; Erik Kristiansson; Viktor Johanson; Ola Nilsson
Journal:  Endocr Relat Cancer       Date:  2018-03       Impact factor: 5.678

4.  Electrophoretic cytopathology resolves ERBB2 forms with single-cell resolution.

Authors:  Chi-Chih Kang; Toby M Ward; Jessica Bockhorn; Courtney Schiffman; Haiyan Huang; Mark D Pegram; Amy E Herr
Journal:  NPJ Precis Oncol       Date:  2018-03-22

5.  Differences between Well-Differentiated Neuroendocrine Tumors and Ductal Adenocarcinomas of the Pancreas Assessed by Multi-Omics Profiling.

Authors:  Teresa Starzyńska; Jakub Karczmarski; Agnieszka Paziewska; Maria Kulecka; Katarzyna Kuśnierz; Natalia Żeber-Lubecka; Filip Ambrożkiewicz; Michał Mikula; Beata Kos-Kudła; Jerzy Ostrowski
Journal:  Int J Mol Sci       Date:  2020-06-23       Impact factor: 5.923

Review 6.  Molecular Signatures and Their Clinical Utility in Pancreatic Neuroendocrine Tumors.

Authors:  Praveen Dilip Chatani; Sunita Kishore Agarwal; Samira Mercedes Sadowski
Journal:  Front Endocrinol (Lausanne)       Date:  2021-01-18       Impact factor: 5.555

7.  Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs).

Authors:  Alberto Puccini; Kelsey Poorman; Mohamed E Salem; Davide Soldato; Andreas Seeber; Richard M Goldberg; Anthony F Shields; Joanne Xiu; Francesca Battaglin; Martin D Berger; Ryuma Tokunaga; Madiha Naseem; Afsaneh Barzi; Syma Iqbal; Wu Zhang; Shivani Soni; Jimmy J Hwang; Philip A Philip; Stefania Sciallero; W Michael Korn; John L Marshall; Heinz-Josef Lenz
Journal:  Clin Cancer Res       Date:  2020-09-03       Impact factor: 12.531

8.  Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors.

Authors:  Timon Vandamme; Matthias Beyens; Ken Op de Beeck; Fadime Dogan; Peter M van Koetsveld; Patrick Pauwels; Geert Mortier; Christel Vangestel; Wouter de Herder; Guy Van Camp; Marc Peeters; Leo J Hofland
Journal:  Br J Cancer       Date:  2016-03-15       Impact factor: 7.640

9.  Hierarchical discovery of large-scale and focal copy number alterations in low-coverage cancer genomes.

Authors:  Ahmed Ibrahim Samir Khalil; Costerwell Khyriem; Anupam Chattopadhyay; Amartya Sanyal
Journal:  BMC Bioinformatics       Date:  2020-04-16       Impact factor: 3.169

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.